MedTrace Logo

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

NCT00887601 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-07-30

No results posted yet for this study

Summary

This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.

Conditions

Interventions

DRUG

MK3134

Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.

DRUG

Comparator: Placebo

Placebo capsules only in one of the four treatment periods.

DRUG

Donepezil

Single dose 5 mg donepezil capsules in two of the four treatment periods.

DRUG

MK3134

Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887601 on ClinicalTrials.gov